Jacobio’s IND Accepted for Phase I/II Trial of BET Inhibitor JAB-8263
Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of...
Category : Clinical Research, Pharma & Healthcare Financing
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis
Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In...
Javara, Cape Fear Partner to Expand Clinical Trial Access
Dedicated to expanding clinical trial access through collaboration with community-based healthcare systems, Javara today announced a new strategic partnership with Cape Fear Valley Health. Leveraging Javara’s integrated teams...
Alpha Cognition Reports Positive Preclinical Data for ALPHA-1062
Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced preclinical data...
Nuravax, IMM to Present Alzheimer’s Vaccine Data at CTAD 2025
Two oral presentations to highlight the safety, immunogenicity, and future development of AV-1959R for primary and secondary prevention of Alzheimer’s disease Nuravax Inc., a clinical-stage...
ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders
Calls for all Avadel Shareholders to vote AGAINST all Director Nominees at the upcoming Annual Meeting ASL Strategic Value Fund, LP (together with its affiliates, “ASL Strategic...
Alto Neuroscience: PAX-D Study Published in The Lancet Psychiatry
– Compelling PAX-D results guided Alto’s acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto...
Lipocine Doses First Patient in Phase 3 Trial for LPCN 1154 PPD
Phase 3 Top Line Results Expected Q2 2026 Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...
Vor Bio, RemeGen Ink Autoimmune Deal, Raise $175M in Funding
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted...
Icon, Varian Partner to Expand Cancer Tech Access in the UK
Icon Group, a global leader in integrated cancer care, has announced a significant new agreement with Varian, a Siemens Healthineers company, involving an investment of...
BioMarin Presents 5-Year Phase 3 Data on ROCTAVIAN® at ISTH 2025
Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis No...
Innovent Presents Phase 3 DREAMS-1 Study of Mazdutide at ADA 85th
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and...
Hemab Therapeutics Shares Positive Data on Bleeding Disorder Pipeline
Sutacimig Phase 2 interim results demonstrate >50% reduction in treated bleeding event and prophylactic treatment potential in Glanzmann thrombasthenia HMB-002 clinical proof-of-mechanism data in Von Willebrand...
Xcell Biosciences Partners with Thermo Fisher to Advance Cell Therapies
Strategic collaboration to innovate Treg and TIL therapies, streamline cell therapy workflows, and enhance manufacturing efficiency Xcell Biosciences (Xcellbio), a San Francisco-based instrumentation company focused...
Sangamo Reports Positive Topline Results from STAAR Study
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and...